Global Technologies, LTD Announces Strategic Pivot and New Agreements in Health & Wellness Sector

Rhea-AI Summary

Global Technologies (GTLL) has announced a strategic pivot focusing on digital health and wellness, following FDA regulatory changes affecting GLP-1 compounding and semaglutide supply. Through its new subsidiary Primecare Supply, LLC, the company has secured two key agreements: a Revenue Share Agreement with a pharmaceutical supplier offering 75% gross margin revenue retention, and a Master Licensing Agreement for AI technology tools at 2.5% of processed transactions. H. Wyatt Flippen has been appointed Chairman while maintaining his CEO role, and the company has removed its clean energy subsidiary president to focus on core operations. GTLL is positioning itself in FDA-compliant pharmaceutical distribution and digital wellness innovation, moving away from its EV sector involvement.

Positive

• Revenue Share Agreement secures 75% of gross margin revenue above supplier floor price
• Strategic pivot to focus on higher-growth digital health and wellness sectors
• Implementation of AI technology tools for digital ordering and operational analytics
• Streamlined leadership structure with CEO H. Wyatt Flippen taking additional role as Chairman

Negative

• Disruption in GLP-1 compounding and semaglutide supply due to FDA regulatory changes
• Discontinuation of clean energy business segment (GOe3, LLC)
• Additional platform fees of 2.5% on processed transactions for AI technology

Greensboro, NC, June 04, 2025 (GLOBE NEWSWIRE) -- Global Technologies, LTD (OTCPK: GTLL), a public, multi-operational company focused on innovation in health and wellness, recently announced corporate developments and commercial milestones signaling a bold pivot in strategy and leadership.

Over the past 90 days, GTLL has responded proactively to external FDA regulatory shifts that disrupted several industry sectors, including GLP-1 compounding and semaglutide supply. These changes catalyzed GTLL’s sharpened focus on the digital health and wellness market, prompting operational streamlining and a commitment to scalable, revenue-focused platforms—particularly through its newly launched subsidiary, Primecare Supply, LLC.

Launch of Primecare Supply and Execution of Key Agreements

As disclosed in its May 30, 2025 Form 8-K filing, GTLL formally launched Primecare Supply, LLC and executed two transformative commercial agreements:

• On May 19, 2025, Primecare entered into a Revenue Share Agreement with a licensed pharmaceutical supplier. Under this structure, Primecare retains 75% of gross margin revenue above the supplier’s floor price while supporting FDA-compliant sales and post-sale obligations to its network of wellness providers.
  
  
• On May 28, 2025, Primecare signed a Master Licensing Agreement with a specialized AI technology partner, gaining access to tools for digital ordering, compliance automation, CRM management, and real-time operational analytics. The platform fee is 2.5% of processed transactions, with a 24-month licensing term.
  

These agreements position Primecare—and GTLL—at the forefront of compliant pharmaceutical distribution and digital wellness innovation.

Leadership Appointments and Strategic Realignment

In line with the Company's refined strategy, H. Wyatt Flippen has been officially appointed Chairman of the Board in addition to his role as Chief Executive Officer. Concurrently, GTLL has removed the President of its clean energy subsidiary, GOe3, LLC, to allow for a full transition away from non-core operations in the EV sector.

“We are building a business that’s leaner, more focused, and directly aligned with FDA-compliant pharmaceutical distribution and digital wellness innovation,” said Flippen. “These agreements and leadership changes reflect our resolve to reduce complexity, expand into higher-growth sectors, and deliver long-term shareholder value.”

A Clearer Path Ahead

GTLL is aggressively expanding its offerings in consumer-facing wellness plans and therapeutic products, leveraging both traditional partnerships and digital infrastructure. The Company is now fully aligned around the growth of its Primecare platform and related ventures, with future announcements anticipated regarding new reseller relationships, patient outreach programs, and proprietary health technologies.

About Global Technologies, LTD

Global Technologies, LTD (OTCPK: GTLL) is a public, multi-operational company committed to building scalable businesses in digital health, wellness, and technology. Through acquisitions, strategic licensing, and integrated platforms, GTLL delivers innovative solutions to improve lives and expand shareholder value.

Forward Looking Statements:

Statements made in this press release that express the Company or management's intentions, plans, beliefs, expectations or predictions of future events, are forward-looking statements. The words "believe," "expect," "intend," "estimate," "anticipate," "will" and similar expressions are intended to further identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Those statements are based on many assumptions and are subject to many known and unknown risks, uncertainties and other factors that could cause the Company's actual activities, results or performance to differ materially from those anticipated or projected in such forward-looking statements. The Company cannot guarantee future financial results; levels of activity, performance or achievements and investors should not place undue reliance on the Company's forward-looking statements. No information contained in this press release should be construed as any indication whatsoever of the Company's future financial performance, future revenues or its future stock price. The forward-looking statements contained herein represent the judgment of the Company as of the date of this press release, and the Company expressly disclaims any intent, obligation or undertaking to update or revise such forward-looking statements to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. No information in this press release should be construed as any indication whatsoever of the Company's future revenues or results of operations.

Investor Contact:
Wyatt Flippen, CEO and Chairman of the Board
W.Flippen@globaltechnologiesltd.info

FAQ

What strategic changes has GTLL announced in June 2025?

GTLL announced a strategic pivot to focus on digital health and wellness, launching Primecare Supply LLC, securing revenue share and AI technology agreements, and streamlining leadership with H. Wyatt Flippen as Chairman and CEO.

What are the key terms of GTLL's Revenue Share Agreement with the pharmaceutical supplier?

The agreement allows Primecare Supply to retain 75% of gross margin revenue above the supplier's floor price while supporting FDA-compliant sales and post-sale obligations.

How much does GTLL pay for the AI technology licensing agreement?

GTLL pays a platform fee of 2.5% of processed transactions with a 24-month licensing term for AI technology tools including digital ordering, compliance automation, and analytics.

Why did GTLL remove its clean energy subsidiary president?

GTLL removed the president of GOe3, LLC to facilitate a complete transition away from non-core operations in the EV sector and focus on its pharmaceutical distribution and digital wellness initiatives.

What caused GTLL to pivot its business strategy in 2025?

GTLL's pivot was catalyzed by external FDA regulatory changes that disrupted several industry sectors, including GLP-1 compounding and semaglutide supply, leading to a focus on digital health and wellness markets.